Insider Selling: Enfusion, Inc. (NYSE:ENFN) Director Sells $17,237.61 in Stock

Enfusion, Inc. (NYSE:ENFN) Director Deirdre Somers sold 1,637 shares of the stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $10.53, for a total value of $17,237.61. Following the transaction, the director now directly owns 41,675 shares of the company’s stock, valued at approximately $438,837.75. The trade was a 3.78 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Enfusion Stock Up 0.9 %

ENFN stock opened at $11.06 on Friday. Enfusion, Inc. has a twelve month low of $7.52 and a twelve month high of $11.38. The stock has a market capitalization of $1.42 billion, a price-to-earnings ratio of 276.44, a price-to-earnings-growth ratio of 1.58 and a beta of 0.95. The firm’s fifty day simple moving average is $10.28 and its two-hundred day simple moving average is $9.28.

Hedge Funds Weigh In On Enfusion

Several hedge funds have recently added to or reduced their stakes in the company. TenCore Partners LP purchased a new position in shares of Enfusion during the third quarter valued at approximately $3,938,000. Dimensional Fund Advisors LP raised its holdings in shares of Enfusion by 57.5% in the second quarter. Dimensional Fund Advisors LP now owns 524,142 shares of the company’s stock worth $4,466,000 after buying an additional 191,436 shares during the period. JPMorgan Chase & Co. raised its holdings in shares of Enfusion by 612.4% in the third quarter. JPMorgan Chase & Co. now owns 208,022 shares of the company’s stock worth $1,974,000 after buying an additional 178,821 shares during the period. Impax Asset Management Group plc grew its position in Enfusion by 25.4% in the 3rd quarter. Impax Asset Management Group plc now owns 676,948 shares of the company’s stock valued at $6,424,000 after acquiring an additional 136,948 shares during the last quarter. Finally, Scalar Gauge Management LLC grew its position in Enfusion by 21.8% in the 2nd quarter. Scalar Gauge Management LLC now owns 613,513 shares of the company’s stock valued at $5,227,000 after acquiring an additional 110,000 shares during the last quarter. 81.05% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the stock. William Blair reissued a “market perform” rating on shares of Enfusion in a report on Monday, January 13th. Stifel Nicolaus lifted their price objective on shares of Enfusion from $11.00 to $13.00 and gave the stock a “buy” rating in a research note on Wednesday, December 18th. Finally, Piper Sandler upped their target price on shares of Enfusion from $10.00 to $11.50 and gave the company a “neutral” rating in a research report on Monday, December 23rd. Three research analysts have rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $10.25.

About Enfusion

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.